acetylated peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-11-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3,108 Da | Consistent with a 28-residue acetylated peptide |
| Residue count | 28 | Corresponds to the amino terminal region of prothymosin alpha |
| Appearance of dry powder | White to off-white solid | Slight variation between lots is normal |
| Solubility class | Freely soluble in water | Low solubility in most organic solvents |
| Common synonyms | Thymosin alpha 1, T alpha 1 | The numeral reflects an early fraction numbering scheme |
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
胸腺素α1对免疫系统的影响涉及多种细胞类型。研究表明，它可促进未成熟T细胞向成熟T细胞分化，并增强T细胞对抗原刺激的增殖反应。树突状细胞在Tα1存在下表达更高水平的共刺激分子，从而更有效地呈递抗原。此外，自然杀伤细胞的活性也观察到上升。这些效应并非直接杀伤病原体，而是调节宿主免疫应答的强度与方向。
在信号层面，Tα1可能通过Toll样受体等模式识别受体发挥作用。部分实验显示，它能激活髓样分化因子88依赖的通路，进而促进核因子κB进入细胞核。这导致白细胞介素2、干扰素γ和白细胞介素12等细胞因子的转录增加。这些细胞因子偏向辅助性T细胞1型应答，有助于细胞免疫。然而，具体受体和结合位点尚未完全确定，不同实验模型的结果存在差异。
临床研究将Tα1用于慢性病毒感染、肿瘤辅助治疗和疫苗佐剂等场景。部分试验报告了免疫学指标改善，但临床终点获益在不同研究中并不一致。系统综述指出，研究间在人群、剂量和联合方案上差异较大，难以汇总结论。因此，Tα1的确切临床地位仍属开放问题，需要更多高质量随机对照试验来澄清。其机制研究也需从体外实验向体内模型推进。
There are drawbacks to each strategy, namely that fluorescent reporters do not allow for enrichment for proteomic analysis, while biotin-based affinity tags co-purify with endogenously biotinylated proteins. A linker group is used to connect the reactive group to the reporter, ideally in a manner that does not alter the activity of probe. The most common linker groups are long alkyl chains, derivatized PEGs, and modified polypeptides. Under the assumption that enzymes vary in their structure, function, and associations depending on a system's physiological or developmental state, it can be inferred that the accessibility of an enzyme's active site will also vary. Therefore, the ability of an ABPP probe to label an enzyme will also vary across conditions. Thus, the binding of a probe can reveal information around an enzyme's functional characteristics in different contexts. High-throughput screening has benefitted from ABPP, particularly in the area of competitive inhibition assays, in which biological samples are pre-incubated with drug candidates, then made to compete with ABPP probes for binding to target enzymes. Compounds with high affinity to their targets will prevent binding of the probe, and the degree of probe binding can be used as an indication of compound affinity. Because ABPP probes label classes of enzymes, this approach can also be used to profile drug selectivity, as highly selective compounds will ideally outcompete probes at only a small number of proteins.
== Awards and honors == Stas Medal of the Belgian Chemical Society (1962) Fellow of the American Academy of Arts and Sciences (1966) Fritz Pregl Medal of the Austrian Microchemical Society (1977) NASA Exceptional Scientific Achievement Medal (1977) Guggenheim Fellow (1983) Field and Franklin Award in Applied Mass Spectrometry from the American Chemical Society (1986) ACS Analytical Chemistry Award from the American Chemical Society (2001) Thomson Medal from the International Mass Spectrometry Foundation (1991) Pehr Edman Award (1992) Member of the National Academy of Sciences (1993) Beckman-ABRF Award from the Association of Biomolecular Resource Facilities (1995) Benjamin Franklin Medal in Chemistry from the Franklin Institute (2007)
== History and programs == GAVI was created in 2000 as a successor to the Children's Vaccine Initiative, which was launched in 1990. In August 2014, Gavi changed its name from "GAVI Alliance" and rebranded itself with a new logo deliberately reminiscent of UN organization logos, but using green as a mark of difference. As mentioned above, Gavi plans its operations in terms of five-year stretegies to make it easier to negotiate longer-term deals. Gavi 6.0 (2026–2030) was approved by the Gavi board in June 2024. One of the goals is to build country-led, sustainable vaccination programs.
Sources: en.wikipedia.org
=== Hemolytic disease of the fetus and newborn === Incompatibility of fetal and maternal RhD antigens is the main cause of Hemolytic disease of the newborn. Approximately 15 percent of Caucasian women, 3 to 5 percent of black Africa women and less than 3 percent of Asian women are RhD negative. Accurate prenatal diagnosis is important because the disease can be fatal to the newborn and because treatment including intramuscular immunoglobulin (Anti-D) or intravenous immunoglobulin can be administered to mothers at risk. PCR to detect RHD (gene) gene exons 5 and 7 from cffDNA obtained from maternal plasma between 9 and 13 weeks gestation gives a high degree of specificity, sensitivity and diagnostic accuracy (>90 percent) when compared to RhD determination from newborn cord blood serum. Similar results were obtained targeting exons 7 and 10. Droplet digital PCR in fetal RhD determination was comparable to a routine real-time PCR technique. Routine determination of fetal RhD status from cffDNA in maternal serum allows early management of at risk pregnancies while decreasing unnecessary use of Anti-D by over 25 percent.
Established in 1994, TESEV is an independent non-governmental think tank, analyzing social, political and economic policy issues facing Turkey. TESEV has raised issues about Islam and democracy, combating corruption, state reform, and transparency and accountability. TESEV serve as a bridge between academic research and policy-making. Its core program areas are democratization, good governance, and foreign policy. Other notable Turkish think tanks are the International Strategic Research Organisation (USAK), the Foundation for Political, Economic and Social Research (SETA), and the Wise Men Center for Strategic Studies (BİLGESAM).
== External links == Overview of Colombian–FARC Peace Process Who are the victims? – The aftermath of violence in Colombia – (Former combatants in Colombia's internal armed conflict spent two years painting their experiences. They face difficult decisions about what to remember, what to forget and how to forgive) "Colombia Page on InSight Crime". Archived from the original on July 26, 2011. Retrieved March 29, 2011. (Ongoing reporting on the Colombian conflict and active criminal groups) "Evolution of the Colombian Civil War". Paul Wolf. Archived from the original on February 3, 2006. Retrieved February 24, 2006. (collection of declassified U.S. documents online) Michael Evans, ed. (May 3, 2002). "War in Colombia: Guerrillas, Drugs and Human Rights in U.S.-Colombia Policy, 1988–2002". National Security Archive Electronic Briefing Book No. 69. National Security Archive. "America's Other War: Terrorizing Colombia". Retrieved February 25, 2006.{{cite web}}: CS1 maint: deprecated archival service (link) Plan Colombia by Carmen Guhn-Knight "Rule of Law in Armed Conflict: Colombia". RULAC Project. Archived from the original on July 6, 2011. Retrieved March 23, 2009. "Q&A: Colombia's civil conflict". BBC News. December 23, 2009. Retrieved February 24, 2006. "Colombia Program". Center for International Policy. Retrieved February 24, 2006. "Accord issue on Colombia's peace process". Alternatives to war. Archived from the original on November 17, 2006. Retrieved November 18, 2006. (In Spanish and English with chronology and key texts and agreements) "CERAC".
Sources: en.wikipedia.org
Baechu-kimchi (배추김치) spicy napa cabbage kimchi, made from whole cabbage leaves Baechu-geotjeori (배추겉절이) unfermented napa cabbage kimchi Bossam-kimchi (보쌈김치) wrapped kimchi Baek-kimchi (백김치) white kimchi, made without chili pepper Dongchimi (동치미) a non-spicy watery kimchi Nabak-kimchi (나박김치) a mildly spicy watery kimchi Chonggak-kimchi (총각김치) cubed chonggak "ponytail" radish, a popular spicy kimchi Kkakdugi (깍두기) spicy cubed Korean radish strongly-scented kimchi containing fermented shrimp Oi-sobagi (오이소박이) cucumber kimchi that can be stuffed with seafood and chili paste, and is a popular choice during the spring and summer seasons Pa-kimchi (파김치) spicy green onion kimchi Yeolmu-kimchi (열무김치) is also a popular choice during the spring and summer, and is made with yeolmu radishes, and does not necessarily have to be fermented. Gat-kimchi (갓김치), made with Indian mustard Yangbaechu-kimchi (양배추 김치) spicy cabbage kimchi, made from "headed" cabbage leaves (as opposed to napa cabbage) Kimchi from the northern parts of Korea tend to have less salt and red chili and usually do not include brined seafood for seasoning. Northern kimchi often has a watery consistency. Kimchi made in the southern parts of Korea, such as Jeolla Province and Gyeongsang Province, uses salt, chili peppers and myeolchijeot (멸치젓, brined anchovy allowed to ferment) or saeujeot (새우젓, brined shrimp allowed to ferment), myeolchiaekjeot (멸치액젓), anchovy fish sauce, kkanariaekjeot (까나리액젓), liquid anchovy jeot, similar to fish sauce used in Southeast Asia, but thicker.
Radon is an invisible, radioactive atomic gas that results from the radioactive decay of radium, which may be found in rock formations beneath buildings or in certain building materials themselves. Radon is probably the most pervasive serious hazard for indoor air in the United States and Europe. It is a major cause of lung cancer, responsible for 3–14% of cases in countries, leading to tens of thousands of deaths. Radon gas enters buildings as a soil gas. As it is a heavy gas it will tend to accumulate at the lowest level. Radon may also be introduced into a building through drinking water particularly from bathroom showers. Building materials can be a rare source of radon, but little testing is carried out for stone, rock or tile products brought into building sites; radon accumulation is greatest for well insulated homes. There are simple do-it-yourself kits for radon gas testing, but a licensed professional can also check homes. The half-life for radon is 3.8 days, indicating that once the source is removed, the hazard will be greatly reduced within a few weeks. Radon mitigation methods include sealing concrete slab floors, basement foundations, water drainage systems, or by increasing ventilation. They are usually cost effective and can greatly reduce or even eliminate the contamination and the associated health risks. Radon is measured in picocuries per liter of air (pCi/L) or becquerel per cubic meter (Bq m-3). Both are measurements of radioactivity. The World Health Organization (WHO) sets the ideal indoor radon levels at 100 Bq/m-3.
=== PRC government === The Chinese government said that producers violating the law "could have their licenses revoked and be handed over to law enforcement organs". A senior Agriculture Ministry official said that of a quarter of a million feed-makers and animal farms inspected for melamine contamination, inspectors found more than 500 engaged in "illegal or questionable practices". Some 3,700 tonnes of feed with excessive melamine were seized. Hong Kong regulators have requested certification of exported eggs, but the central government has not yet mounted a centralised response; although mainland authorities already require eggs to be certified as free of avian influenza and Sudan red dye prior to export following previous food-safety scares, the AQSIQ has declined nationwide testing. Local government, for example Guangdong authorities, have increased random inspections at poultry farms. They declared to "harshly crack down on the unlawful behaviour of illegally manufacturing, selling and using melamine".
The DNA passing through the nanopore changes its ion current. This change is dependent on the shape, size and length of the DNA sequence. Each type of the nucleotide blocks the ion flow through the pore for a different period of time. The method does not require modified nucleotides and is performed in real time. Nanopore sequencing is referred to as "third-generation" or "long-read" sequencing, along with SMRT sequencing. Early industrial research into this method was based on a technique called 'exonuclease sequencing', where the readout of electrical signals occurred as nucleotides passed by alpha(α)-hemolysin pores covalently bound with cyclodextrin. However the subsequent commercial method, 'strand sequencing', sequenced DNA bases in an intact strand. Two main areas of nanopore sequencing in development are solid state nanopore sequencing, and protein based nanopore sequencing. Protein nanopore sequencing utilizes membrane protein complexes such as α-hemolysin, MspA (Mycobacterium smegmatis Porin A) or CssG, which show great promise given their ability to distinguish between individual and groups of nucleotides. In contrast, solid-state nanopore sequencing utilizes synthetic materials such as silicon nitride and aluminum oxide and it is preferred for its superior mechanical ability and thermal and chemical stability. The fabrication method is essential for this type of sequencing given that the nanopore array can contain hundreds of pores with diameters smaller than eight nanometers.
Sources: en.wikipedia.org
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.
The two share a family name but have different sequences, sizes, and functions. Thymosin beta-4 is a 43-residue peptide associated with actin binding and cell migration. Thymosin alpha-1 is a 28-residue peptide linked mainly to immune signaling.
Thymalfasin is the assigned international nonproprietary name for the synthetic 28-residue peptide. Thymosin alpha-1 is the descriptive research name for the same molecule. Which term appears depends on the context and the regulatory document.